Endothelin Concentrations in a Population With Cardiovascular Disease and Periodonitis

Serum; Disease Clinical Trial

Official title:

Analysis of Endothelin Concentrations in a Population With Cardiovascular Disease and Periodontitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04152005
• Other study ID #: 10-918-10
• Status: Completed
• Start date: January 1, 2016
• Est. completion date: September 30, 2018

Study information

• Verified date: November 2019
• Source: University of Messina
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Recently, a key role played in the ethiology of periodontitis has been highlighted by a Endothelin (ET-1). ET1 possess the ability to express surface antigens of endothelial and hematopoietic stem cells and to assist in maintaining vascular integrity and the repair mechanism of the endothelium. ET originate from bone marrow

Description:

The aim of the present study was to investigate the association between ET-1 in patients with periodontitis. Furthermore, the objective was to determine if the periodontal status influenced ET-1 levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 165
• Est. completion date: September 30, 2018
• Est. primary completion date: September 25, 2018
• Gender: All
• Age group: 21 Years to 71 Years

Eligibility

Inclusion Criteria:

• Presence of at least 16 teeth

• CP with a minimum of 40% of sites with a clinical attachment level (CAL)

=2mm and probing depth (PD) =4mm;

• Presence of at least =2 mm of crestal alveolar bone loss verified on digital periapical radiographs

• Presence of =40% sites with bleeding on probing (BOP)

Exclusion Criteria:

• Intake of contraceptives

• Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study

• Status of pregnancy or lactation

• Previous history of excessive drinking

• Allergy to local anaesthetic

• Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Serum; Disease

Intervention

Other:
• Observation
Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease

Locations

Country	Name	City	State
Italy	University of Messina	Messina

Sponsors (1)

Lead Sponsor	Collaborator
University of Messina

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of ET-1 levels	Correlation of ET-1 levels with periodontal and cardiovascular disease	1 year